Trial Profile
A Phase 2 Study Extension Period of Pegylated Somatropin (PEG-somatropin) in the Treatment of Children With Idiopathic Short Stature: An Open, Non-controlled Observational Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 21 Jun 2023 Planned End Date changed from 1 Jun 2026 to 1 Jun 2030.
- 21 Jun 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2030.
- 21 Jun 2023 Status changed from recruiting to active, no longer recruiting.